Literature DB >> 22997369

CT grading of lung disease in lymphangioleiomyomatosis.

Jianhua Yao1, Angelo M Taveira-DaSilva, Thomas V Colby, Joel Moss.   

Abstract

OBJECTIVE: The aim of this study was to determine whether a CT-based method shows lung lesions, grades disease severity, and evaluates lung tissue in areas adjacent to or remote from cysts in patients with lymphangioleiomyomatosis (LAM), a cystic lung disease that may cause respiratory failure and death.
MATERIALS AND METHODS: Three hundred twenty-six CT examinations of 52 patients with LAM were studied. After the lungs had been divided into segments and images had been subdivided into texture blocks, a multidimensional feature vector was used to differentiate and group each texture block. Cysts were outlined, and texture around and away from cysts was analyzed. Sequential CT scans and pulmonary function test results were evaluated to assess the trend of change. Histopathologic examinations were performed of biopsy specimens from 45 patients.
RESULTS: Differences in texture features between areas adjacent to and areas remote from the cysts were observed. The cyst score and sum entropy in areas around the cysts correlated with lung function (p<0.0001). Emphysematouslike changes in noncystic areas were identified in lung tissue of 31 of 45 patients.
CONCLUSION: A computational method that uses texture analysis and feature correlation can identify and quantify cystic areas where LAM exists and can detect abnormalities in areas near cysts. Pathologic data also show lung damage in areas adjacent to cysts. Several texture features correlate with lung function. Declines in lung function paralleled changes in texture features. In LAM, cystic changes alone may not define the extent of lung destruction.

Entities:  

Mesh:

Year:  2012        PMID: 22997369     DOI: 10.2214/AJR.11.7888

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  14 in total

1.  Mounier-Kuhn Syndrome Mimicking Lymphangioleiomyomatosis.

Authors:  Gustavo G Pacheco; Amanda M Jones; Jianhua Yao; David E Kleiner; Angelo M Taveira-DaSilva; Joel Moss
Journal:  Chest       Date:  2018-02       Impact factor: 9.410

2.  Effects of sirolimus in lymphangioleiomyomatosis patients on lung cysts and pulmonary function: long-term follow-up observational study.

Authors:  Cherry Kim; Kyung-Hyun Do; Jaehyung Cha; Jin Woo Song; Sang Min Lee; Ki Yeol Lee
Journal:  Eur Radiol       Date:  2019-08-30       Impact factor: 5.315

Review 3.  Lung densitometry: why, how and when.

Authors:  Mario Mascalchi; Gianna Camiciottoli; Stefano Diciotti
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

4.  Clinical CT underestimation of the percentage volume occupied by cysts in patients with lymphangioleiomyomatosis.

Authors:  Thomas C Larsen; Amir M Hasani; Shirley F Rollison; Tania R Machado; Amanda M Jones; Patricia Julien-Williams; Marcus Y Chen; Joel Moss; Han Wen
Journal:  Clin Imaging       Date:  2019-11-27       Impact factor: 1.605

5.  Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.

Authors:  Jianhua Yao; Angelo M Taveira-DaSilva; Amanda M Jones; Patricia Julien-Williams; Mario Stylianou; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2014-12-01       Impact factor: 21.405

6.  Evaluation of the extent of pulmonary cysts and their association with functional variables and serum markers in lymphangioleiomyomatosis (LAM).

Authors:  Bruno Guedes Baldi; Mariana Sponholz Araujo; Carolina Salim Gonçalves Freitas; Gustavo Borges da Silva Teles; Ronaldo Adib Kairalla; Olívia Meira Dias; Daniel Antunes Silva Pereira; Suzana Pinheiro Pimenta; Carlos Roberto Ribeiro Carvalho
Journal:  Lung       Date:  2014-09-09       Impact factor: 2.584

7.  Chest CT Scan at Radiation Dose of a Posteroanterior and Lateral Chest Radiograph Series: A Proof of Principle in Lymphangioleiomyomatosis.

Authors:  Eileen Hu-Wang; John L Schuzer; Shirley Rollison; Eric S Leifer; Chloe Steveson; Vissaagan Gopalakrishnan; Jianhua Yao; Tania Machado; Amanda M Jones; Patricia Julien-Williams; Joel Moss; Marcus Y Chen
Journal:  Chest       Date:  2018-10-03       Impact factor: 9.410

8.  EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.

Authors:  Angelo M Taveira-DaSilva; Joel Moss
Journal:  Expert Opin Orphan Drugs       Date:  2016-03-07       Impact factor: 0.694

Review 9.  Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-DaSilva; Joel Moss
Journal:  Clin Epidemiol       Date:  2015-04-07       Impact factor: 4.790

10.  Rates of change in FEV1 and DLCO as potential indicators for mTOR inhibitor therapy in premenopausal lymphangioleiomyomatosis patients.

Authors:  Angelo M Taveira-DaSilva; Patricia Julien-Williams; Amanda M Jones; Mario Stylianou; Joel Moss
Journal:  Eur Respir J       Date:  2018-04-19       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.